Naveed Siddiqi joined Novo Holdings in 2019 and works from London and Copenhagen as a Senior Partner in Venture Investments. Novo Holdings says he brings more than 25 years of experience in life science investments and investment banking. Between 2013 and 2018 he was a Partner at Andera Partners, a Paris-based venture capital and growth equity firm focused on life sciences. He has also worked for Nomura Phase4 Ventures, Nomura International, EFG Corporate Finance and KPMG, and as a medical doctor in the UK's National Health Service. Novo Holdings lists his current board seats as Alentis Therapeutics, Asceneuron, F2G and Windward Bio, alongside past seats at companies that have since been acquired. He holds a medical degree from Guy's and St Thomas's Hospital Medical School and qualified as a Chartered Accountant with the ICAEW.
Education
Medical degree, Guy's and St Thomas's Hospital Medical School (now King's College London)
Chartered Accountant, Institute of Chartered Accountants England & Wales
Previous Experience
UK National Health Service - medical doctor
KPMG
EFG Corporate Finance
Nomura International
Nomura Phase4 Ventures
Andera Partners - Partner, life science investing (2013-2018)
Notable Investments
Windward BioWindward BioAlentis Therapeutics
Board Seats
Alentis Therapeutics
Asceneuron
F2G
Windward Bio
Career Timeline
2013
Becomes Partner at Andera Partners, a Paris-based venture capital and growth equity firm, until 2018.
2019
Joins Novo Holdings A/S, working from London and Copenhagen as Senior Partner in Venture Investments.
2025
Named in Novo Holdings' announcement of the USD 200 million Series A for Windward Bio's launch as joining the Windward Bio board of directors.